Gastric PolypPhase 4NCT03065868
Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp
A Phase 4 study testing H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin) in people with Gastric Polyp and Helicobacter Pylori Infection, run by Kyungpook National University Hospital at 1 site in South Korea.
Trial summary
Evaluation of the effect of H. pylori eradication on regression of H. pylori-related gastric polyp (Ranomized controlled trial) 1. Study design: open labeled RCT 2. Study group H. pylori eradication group (N=17), non-eradication group (N=15) 3. Treatment plan 1. Read more about this study
- Who is it for?
- Ages 20 to 70 years
- Conditions the study is for
- Gastric Polyp, Helicobacter Pylori Infection
- What is being tested?
- H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 32 participants
- Where
- 1 siteSouth Korea
- Study dates
- 9 Dec 2015to 30 Apr 2019
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Gastric polyp with current infection of H. pylori
- Gastric polyp size with 3mm-10mm
- Age of 20 yr - 70yr
Who cannot join
- Gastric ulcer ir duodenal ulcer (healing stage or acute stage)
- Use of PPI within 4weeks
- Liver cirrhosis, renal insufficiency, other serious chronic or acute disease
- Current infection of other bacteria, virus, or fungus
- Any cancer, psychologic disease
- Heavy drinker
Show all 13Show fewer
- Drug abuser
- Pregnant women
- Penicillin allergy
- Use of digoxin, antifungal, wafarin
- Previous H. pylori eradication
- Gastric polyp with bleeding or malignant transformation
- Tiny polyp less than 3mm.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp (Randomized Controlled Study)
Evaluation of the effect of H. pylori eradication on regression of H. pylori-related gastric polyp (Ranomized controlled trial)
- Study design: open labeled RCT
- Study group H. pylori eradication group (N=17), non-eradication group (N=15)
- Treatment plan
- Baseline EGD : 0.3-1cm sized polyp - bx \& CLO test (antrum \& body) ==> if H. pylori positive and eligible patients, randomization
- Triple therapy
- UBT (4week after eradication)
- Follow-up EGD: gross finding, CLO test
- Evaluation of polyp regression
- disappear
- regression over 50% (size, number)
- no change or increase (size, number)
Read the detailed description
(A) Study population
- inclusion HP-realetd polyp polyp size with 0.3cm-1cm 20 yr - 70yr
- exclusion peptic ulcer, healing stage or acute stage recent use of PPI within 4weeks Liver cirrhosis, renal insufficiency, other serious chronic or acute disease current infection of other bacteria, virus, or fungus cancer, psychologic disease heavy drinker drug abuser pregnant women, Penicillin allergy, digoxin, antifungal, wafarin previosu H. pylori eradication enroll gastric polyp with bleeding or malignant transformation tiny polyp less than 3mm. (B) Study method
- Study design: open labeled RCT
- Study group H. pylori eradication group (N=17), non-eradication group (N=15)
- Treatment plan
- Baseline EGD: 0.3-1cm sized polyp - bx \& CLO test (antrum \& body) ==> if H. pylori positive and eligible patients, randomization
- Triple therapy
- UBT (4week after eradication) if eradication failure in triple therapy, 2nd line treatment (metroniazole based quadraple therpay) and the UBT (4week after eradication)
- Follow-up EGD (3-9M): gross finding, CLO test
- Evaluation of polyp regression
- disappear
- regression over 50% (size, number)
- no change or increase (size, number)
- Statistical analysis
- Chi-square test to compare polyp regression between treatment \& control group.
- t-test to compare continuous variables between treatment \& control group.
- Paired T-test to compare the size between baseline and follow-up EGD.
- Regression analysis: univariate \& multivariate analysis.
- Conditions
- Gastric Polyp, Helicobacter Pylori Infection
- Being tested
- H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)
- Keywords
- gastric polyp, Helicobacter pylori eradication
- Medical subject headings
- Polyposis, Gastric
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)Drug
Also called Triple Therapy
- pylori eradication (Triple Therapy) as first line treatment if eradication failure, quadruple therpy will be provided as 2nd line treatment
| Study group | Role | What they receive |
|---|---|---|
| eradictaion | Experimental | H. pylori eradication group Receives: Drug: H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin) |
| non-eradication | No intervention | H. pylori non-eradication group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Compare regression rate of gastric polyps between H. pylori eradication and non-eradication groups. Regression of gastric polyp: one of below 1) Disappearance of gastric polyp 2) Reduction of polyp size over 50%
Evaluation of the effect of H. pylori eradication on the regression of H. pylori associated gastric polyp
Study group
- H. pylori eradication
- H. pylori non-eradication
Definition of gastric polyp change:
- Disappearance of gastric polyp
- Reduction of polyp size over 50%
- No change of size or increased size
Measured: up to 24months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Feb 2017
- Study start9 Dec 2015
- Primary completion30 Apr 2019
- Study completion30 Apr 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Gastric PolypStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- open labelled randomized controlled trial. randomization : 2015 September
- Masking
- None (open label)
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kyungpook National University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Su Youn Nam, Kyungpook National University Chilgok Hospital
- Investigators
- Su Youn Y Nam, MD, PhD, Principal investigator, Kyungpook National University Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03065868
- Sponsor's protocol ID
- KNUMC_15-1045
- Status last verified
- Sep 2019
- First submitted
- 18 Feb 2017
- Last updated
- 26 Sep 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Nam SY, Lee SW, Jeon SW, Kwon YH, Lee HS. Helicobacter pylori Eradication Regressed Gastric Hyperplastic Polyp: A Randomized Controlled Trial. Dig Dis Sci. 2020 Dec;65(12):3652-3659. doi: 10.1007/s10620-020-06065-0. Epub 2020 Jan 23.
PubMed 31974914
Study at a glance
From the registry record, last updated by the sponsor on 26 Sep 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp (Randomized Controlled Study)
- ClinicalTrials.gov ID
- NCT03065868
- Acronym / sponsor ID
- KNUMC_15-1045
- Conditions
- Gastric Polyp, Helicobacter Pylori Infection
- Keywords
- gastric polyp, Helicobacter pylori eradication
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 32 participants (actual)
- Lead sponsor
- Kyungpook National University HospitalUniversity, hospital or other
- Study start
- 9 Dec 2015 (actual)
- Primary completion
- 30 Apr 2019 (actual)
- Study completion
- 30 Apr 2019 (actual)
- First posted
- 28 Feb 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Evaluation of the effect of H. pylori eradication on regression of H. pylori-related gastric polyp (Ranomized controlled trial)
- Study design: open labeled RCT
- Study group H. pylori eradication group (N=17), non-eradication group (N=15)
- Treatment plan
- Baseline EGD : 0.3-1cm sized polyp - bx \& CLO test (antrum \& body) ==> if H. pylori positive and eligible patients, randomization
- Triple therapy
- UBT (4week after eradication)
- Follow-up EGD: gross finding, CLO test
- Evaluation of polyp regression
- disappear
- regression over 50% (size, number)
- no change or increase (size, number)
Detailed description
(A) Study population
- inclusion HP-realetd polyp polyp size with 0.3cm-1cm 20 yr - 70yr
- exclusion peptic ulcer, healing stage or acute stage recent use of PPI within 4weeks Liver cirrhosis, renal insufficiency, other serious chronic or acute disease current infection of other bacteria, virus, or fungus cancer, psychologic disease heavy drinker drug abuser pregnant women, Penicillin allergy, digoxin, antifungal, wafarin previosu H. pylori eradication enroll gastric polyp with bleeding or malignant transformation tiny polyp less than 3mm. (B) Study method
- Study design: open labeled RCT
- Study group H. pylori eradication group (N=17), non-eradication group (N=15)
- Treatment plan
- Baseline EGD: 0.3-1cm sized polyp - bx \& CLO test (antrum \& body) ==> if H. pylori positive and eligible patients, randomization
- Triple therapy
- UBT (4week after eradication) if eradication failure in triple therapy, 2nd line treatment (metroniazole based quadraple therpay) and the UBT (4week after eradication)
- Follow-up EGD (3-9M): gross finding, CLO test
- Evaluation of polyp regression
- disappear
- regression over 50% (size, number)
- no change or increase (size, number)
- Statistical analysis
- Chi-square test to compare polyp regression between treatment \& control group.
- t-test to compare continuous variables between treatment \& control group.
- Paired T-test to compare the size between baseline and follow-up EGD.
- Regression analysis: univariate \& multivariate analysis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- open labelled randomized controlled trial. randomization : 2015 September
| Arm | Type | Receives |
|---|---|---|
| eradictaion | Experimental | Drug: H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)H. pylori eradication group |
| non-eradication | No intervention | –H. pylori non-eradication group |
Who may qualify
- Ages
- 20 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Gastric polyp with current infection of H. pylori
- Gastric polyp size with 3mm-10mm
- Age of 20 yr - 70yr
Key exclusion criteria (13 listed)
- Gastric ulcer ir duodenal ulcer (healing stage or acute stage)
- Use of PPI within 4weeks
- Liver cirrhosis, renal insufficiency, other serious chronic or acute disease
- Current infection of other bacteria, virus, or fungus
- Any cancer, psychologic disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)Also: Triple TherapyH. pylori eradication (Triple Therapy) as first line treatment if eradication failure, quadruple therpy will be provided as 2nd line treatment | Drug | eradictaion |
Primary outcome
Compare regression rate of gastric polyps between H. pylori eradication and non-eradication groups. Regression of gastric polyp: one of below 1) Disappearance of gastric polyp 2) Reduction of polyp size over 50%
Time frame: up to 24months
Evaluation of the effect of H. pylori eradication on the regression of H. pylori associated gastric polyp Study group 1. H. pylori eradication 2. H. pylori non-eradication Definition of gastric polyp change: 1. Disappearance of gastric polyp 2. Reduction of polyp size over 50% 3. No change of size or increased size
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Sep 2019.
- Derived from this study: PubMed 31974914Nam SY, Lee SW, Jeon SW, Kwon YH, Lee HS. Helicobacter pylori Eradication Regressed Gastric Hyperplastic Polyp: A Randomized Controlled Trial. Dig Dis Sci. 2020 Dec;65(12):3652-3659. doi: 10.1007/s10620-020-06065-0. Epub 2020 Jan 23.
- Individual participant dataSharing planned: No
Related trials for Gastric Polyp
RecruitingObservational study
New bioMarkers tO straTIfy cOlorectal caNcer Referrals
Colorectal Carcinoma, Polyp
Enrolling by invitationObservational study
UC Davis Cohort of Pre-Malignant and Malignant Gastro-Intestinal DisEases Study
Intestinal Metaplasia, Chronic Gastritis
RecruitingObservational study
Integrated Cancer Repository for Cancer Research
Pancreatic Cancer, Thyroid Cancer
Not yet recruitingObservational study
Recurrence After Gastric and Intestinal Polyp Resection
Gastric Polyps, Intestinal Polyps
RecruitingObservational study
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
Colorectal Cancer, Esophageal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Su Youn Y Nam, MD, PhD principal investigator
Kyungpook National University Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin) in people with Gastric Polyp and Helicobacter Pylori Infection, run by Kyungpook National University Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compare regression rate of gastric polyps between H. pylori eradication and non-eradication groups. Regression of gastric polyp: one of below 1) Disappearance of gastric polyp 2) Reduction of polyp size over 50% (time frame: up to 24months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03065868, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Sep 2019.